Sign In
Buy NMTR
$0.0722
+0 (+0%)
At Close: Nov 20, 2023
-Study May Proceed Letter Received from FDA Under Investigator IND- -EBRIS plans to initiate Phase 2a trial in MIS-C in Q4 2021 at Massachusetts General Hospital for Children- -Translational evidence
9 Meters Biopharma Provides Business Update and Reports Financial Results for the Second Quarter 2021
08:30am, Thursday, 12'th Aug 2021
- Initiated Phase 2 VIBRANT study of vurolenatide for short bowel syndrome (SBS) in Q2; total stool output (TSO) is primary endpoint following FDA guidance - - Expect Phase 2 data from VIBRANT in Q4 2
9 Meters Biopharma, Inc. to participate in BMO Capital Markets' "Biopharma Spotlight Series: Innovation in GI"
08:30am, Thursday, 05'th Aug 2021
Conference Call Scheduled for August 12, 2021 RALEIGH, NC / ACCESSWIRE / August 5, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), today announced that the Executive Management team will participate
Hot Penny Stocks to Buy Now? 4 You Need to Know About
05:06pm, Thursday, 22'nd Jul 2021
These hot penny stocks may deserve a place on your watchlist this month The post Hot Penny Stocks to Buy Now? 4 You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Informatio
7 Penny Stocks To Buy According To Analysts With Targets Up To 316%
01:26pm, Thursday, 22'nd Jul 2021
Analysts say these are penny stocks to buy. Do you agree?
9 Meters Biopharma Acquires Anti-GIP Monoclonal Antibody For Obesity-Related Disorders
09:32am, Monday, 19'th Jul 2021
9 Meters Biopharma Inc (NASDAQ: NMTR) has acquired global development rights to LOB-0136 (now known as NM-136) that targets glucose-dependent insulinotropic polypeptide (GIP) from Lobesity LLC. GIP
9 Meters Biopharma, Inc. Announces the Acquisition of Humanized Anti-GIP Monoclonal Antibody from Lobesity
08:30am, Monday, 19'th Jul 2021
- Broadens existing pipeline with a monoclonal antibody against a novel target, glucose-dependent insulinotropic polypeptide (GIP) - - First planned indication is Prader-Willi Syndrome- - IND-enabling
Best 3 Penny Stocks to Watch Right Now, Worth it or Not?
05:02pm, Wednesday, 14'th Jul 2021
Which penny stocks are the best for your watchlist in 2021? The post Best 3 Penny Stocks to Watch Right Now, Worth it or Not?
9 Meters Biopharma, Inc. To Present at the William Blair Biotech Focus Conference
07:30am, Thursday, 08'th Jul 2021
RALEIGH, NC / ACCESSWIRE / July 8, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO
7 Trending Penny Stocks That You Need to Know About in July 2021
04:26pm, Wednesday, 30'th Jun 2021
Are these trending penny stocks worth adding to your watchlist? The post 7 Trending Penny Stocks That You Need to Know About in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Informa
9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome
07:30am, Monday, 14'th Jun 2021
Initiating the largest Phase 2 placebo-controlled trial in short bowel syndrome Topline results of the multicenter VIBRANT study anticipated in Q4 2021 RALEIGH, NC / ACCESSWIRE / June 14, 2021 / 9 Met
9 Meters Biopharma, Inc. to Present at 2021 BIO Digital
07:30am, Wednesday, 09'th Jun 2021
RALEIGH, NC / ACCESSWIRE / June 9, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that John Temperato, CEO
Is the Options Market Predicting a Spike in 9 Meters Biopharma (NMTR) Stock?
11:16am, Wednesday, 19'th May 2021
Investors need to pay close attention to 9 Meters Biopharma (NMTR) stock based on the movements in the options market lately.
CORRECTION 9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
10:15am, Tuesday, 18'th May 2021
This version of the release contains a corrected hyperlink. RALEIGH, NC / ACCESSWIRE / May 19, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs i
9 Meters Biopharma, Inc. to Present at Oppenheimer's Rare & Orphan Disease Summit
07:30am, Tuesday, 18'th May 2021
RALEIGH, NC / ACCESSWIRE / May 18, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO,
